Precision announces return of programs, conclusion of collab with Prevail

Precision BioSciences (DTIL) announced the anticipated return of three programs from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (LLY). Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration. Precision uses its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision. “We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs. Together, we advanced three programs from concept toward clinical candidates, and Precision completed its workplan for these programs to the next stage gate, taking us to an important development decision point,” said Michael Amoroso, President and Chief Executive Officer of Precision BioSciences. “Our decision to regain control of the programs brings exciting development opportunities to Precision’s pipeline with a focus on benefiting people born with incurable genetic diseases.”